NEW YORK, May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/bluebird-bio-loss-submission-form/?id=80713&from=4 CLASS PERIOD: April 24, 2023 to D ...

LOS ANGELES, May 16, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Class Period: April 24, 2023 – December 8, 2023 Lead Plaintiff Deadline: May 28, 2024 If you wish to serve as lead plaintiff of the bluebird lawsuit, you can submit your contact information at www.glancylaw.com/cases/bluebird-bio-Inc-1/. You can ...

It won't be easy for the company to bounce back. Being a highly innovative company isn't a sufficient condition for success in the biotech industry. Bluebird Bio (BLUE), a small-cap gene-editing specialist, is a good example of this. Though the company has developed groundbreaking therapies, the stock has significantly lagged the market in recent years. Still, if Bluebird Bio can turn things around, the company could deliver explosive returns to investors who initiate a position today. Is Bluebird Bio worth ...

财务数据和关键指标变化 - 公司在第一季度报告了1860万美元的总收入,主要来自ZYNTEGLO的收入 [3][11] - 公司预计2024年的毛利率折扣率将在20%-25%之间,取决于产品组合、支付方式以及结果协议的利用情况 [11] - 截至3月31日,公司拥有2.64亿美元的现金,包括5200万美元的受限现金,预计现金可持续到2026年第一季度 [11] 各条业务线数据和关键指标变化 - LYFGENIA在美国的首次商业细胞采集已完成,这是一个重要里程碑 [4] - ZYNTEGLO在2024年初以来已有11例患者开始治疗,公司正在采取措施增加ZYNTEGLO和SKYSONA的产品制造能力 [7] - SKYSONA在2024年初以来已有3例患者开始治疗 [7] - 公司预计2024年全年的患者启动数将在85-105例之间 [7][62] 各个市场数据和关键指标变化 - 公司已在5个月内为LYFGENIA的商业和医疗保险患者成功获得事先授权 [8] - 公司已与多家全国性商业保险公司签署了LYFGENIA的结果协议,并为超过2亿美国人建立了覆盖政策 [8] - 公司正在与代表80%医疗补助受益人的医疗补助机构进行讨论 [8] - ZYNTEGLO和SKYSONA的及时获得医疗补助和商业保险的报销一直持续,没有最终拒绝 [8] 公司战略和发展方向及行业竞争 - 公司目前专注于美国市场,未来可能会考虑与合作伙伴进入海外市场 [56] - 公司已建立64个合格治疗中心,是同行业中最多的,并计划在2024年增加少量中心 [9][29][31] - 公司正在将销售团队的重点从开发新的合格治疗中心转移到支持现有中心的患者转化上 [46] 管理层对经营环境和未来前景的评论 - 公司对LYFGENIA的商业发布和患者启动感到兴奋,预计未来几个季度会看到加速增长 [4][12] - 公司对ZYNTEGLO和SKYSONA的发展进度感到满意,预计ZYNTEGLO在2024年会有强劲的线性增长,SKYSONA会有5-10例患者启动 [7][10] - 公司对sickle cell社区的合作伙伴关系感到自豪,并期待未来继续推进LYFGENIA的发展 [4] 问答环节重要的提问和回答 问题1 **Jason Gerberry 提问** 询问LYFGENIA在医疗补助报销方面是否存在障碍 [14] **Tom Klima 回答** 医疗补助报销不是限制因素,公司一直在与医疗补助机构合作,确保他们认识到一次性潜在治愈疗法的价值,并提供结果协议 [16][17] 问题2 **Gena Wang 提问** 询问64个合格治疗中心中有多少已经为LYFGENIA接收了患者转介 [27] **Tom Klima 回答** 约有50个中心已经接收了LYFGENIA的患者转介,预计几乎所有中心都将很快加入 [31] 问题3 **Eric Schmidt 提问** 询问公司如何定义新的患者启动 [39] **Tom Klima 回答** 公司一直保持一致的定义,即首次独特的细胞采集完成即算作新的患者启动 [40]

bluebird bio (BLUE) registered revenues of $18.6 million in the first quarter, up from $2.4 million recorded in the year-ago quarter and beating the Zacks Consensus Estimate of $18 million. The $16.2-million upside can be attributed to increased Zynteglo product revenues. The FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusion on Aug 17, 2022, and Skysona for treating early, active cerebral adrenoleukodystrophy (CALD) on Se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________ FORM 8-K __________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 __________________________ bluebird bio, Inc. (Exact name of Registrant as Specified in Its Charter) _____________________________________________________________ Delaware 001-35966 13-3680878 (State or Other Jurisdiction (IRS Em ...

bluebird bio公司 - bluebird bio今年股价下跌25.4%，行业下跌7.9%[1] - FDA批准了bluebird的三种基因疗法，但市场接受度不如预期[1] - bluebird预计2024年将有85-105名患者开始接受其三种获得FDA批准的疗法[1] - bluebird的基因疗法价格较高，可能面临盈利压力[1] - 竞争对手Vertex Pharmaceuticals可能影响bluebird在市场上的份额[1] - FDA批准了Vertex和CRISPR Therapeutics的基因疗法，可能对bluebird构成竞争[1] - bluebird的基因疗法定价较高，可能受到价格更低的竞争对手的挑战[1] - bluebird的财务状况不容乐观，尽管获得了贷款，但投资者对公司的财务能力并不满意[1] - bluebird目前正在重新调整其2022年和2023年的财务报表[1] - bluebird目前的Zacks排名为3（持有）[1] ADMA Biologics, Inc.公司 - ADMA Biologics, Inc.是一家在生物技术领域排名较高的公司，目前Zacks排名为1（强烈买入）[1] - ADMA Biologics在过去60天内，2024年每股收益预期有所提高[1] - ADMA Biologics在过去一年股价上涨了88.5%[1] - ADMA Biologics在过去四个季度中，三次超出预期，一次符合预期，平均超出率为85.00%[1]

Bluebird Bio - Bluebird Bio和Novavax都是生物技术公司，股价在近几年急剧下跌[1] - Bluebird Bio专注于基因编辑，拥有三种已批准上市的产品，其中最有潜力的是治疗镰状细胞病的Lyfgenia[3][4] - Lyfgenia的目标市场潜力巨大，每个疗程的治疗费用为310万美元，Bluebird Bio已与多家第三方支付者达成协议，拥有62个合格治疗中心[5][6] - Bluebird Bio的现金储备足够支撑到2026年，具有创新能力，如果能在目标市场中取得一小部分份额，股价可能会飙升[7] - Bluebird Bio在基因编辑领域已证明能够开发创新疗法，其股价可能被低估，潜在收购者更有可能选择Bluebird Bio而非Novavax[13] Novavax - Novavax也是一家创新公司，去年营收约为10亿美元，正在开发一种潜在的新冠疫苗和流感疫苗的联合疫苗[8][9] - Novavax与Gavi达成协议解决了疫苗订单取消的重大风险，预计今年营收将在8亿至10亿美元之间[10][11] - 尽管Novavax的营收和现金状况看起来更强大，但在新冠疫苗领域处于次要地位，销售可能会继续下降[12]

For most stocks, a 25% cut in an analyst's target price following an earnings release would send investors scrambling for the exit door. That wasn't the case with Bluebird Bio (BLUE -6.23%), however. The clinical-stage biotech saw a decent price rise after those two events in late March. What helped was that, despite the cut, said analyst believes the shares are on track to double in price and then some. The price target is cut. However... That prognosticator is Wells Fargo's Yanan Zhu, who now feels Bluebi ...

bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Conference Call March 26, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of IR Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - CFO Conference Call Participants Jason Gerberry - Bank of America Securities Danielle Brill - Raymond James Jack Allen - Baird Gena Wang - Barclays Eric Joseph - JPMorgan Mani Foroohar - Leerink Jeffrey Hung - Morgan Stanley Salveen Richter - Goldman Sachs Sami Corwin - ...